More than 1.3-billion globally will have diabetes by 2050, study finds

Global ageing and rising body weight will more than double the number of people with diabetes by 2050, researchers predicted, putting millions more people at risk of dangerous disorders.

Fewer than 10% of people with diabetes in low- and middle-income countries receive proper care, say researchers.
Fewer than 10% of people with diabetes in low- and middle-income countries receive proper care, say researchers. (Bloomberg)

Global ageing and rising body weight will more than double the number of people with diabetes by 2050, researchers predicted, putting millions more people at risk of dangerous disorders. 

More than 1.3-billion people worldwide will have diabetes at the half-century mark, up from 529-million in 2021, according to Lancet medical journal estimates released on Thursday. The majority of patients will have type 2 diabetes, the form that’s often linked to being overweight.

A loss of the body’s ability to control blood-sugar levels, diabetes affects one in 10 adults and caused 6.7-million deaths in 2021, the International Diabetes Federation estimates. The disease has unequal impacts, with fewer than 10% of people affected in low- and middle-income countries receiving proper care, said the Lancet researchers.

“If we don’t do anything,” said Kanyin Liane Ong, a researcher at the University of Washington’s Institute for Health Metrics and Evaluation and the lead author of the study, “it will cause a huge burden.”

Type 2 is the most common form of diabetes, accounting for about 96% of cases. It occurs when the body’s cells stop responding properly to insulin, which can lead to chronic high blood-sugar levels that leave patients vulnerable to heart, kidney, eye and nerve damage. Though preventable in many cases, usually with weight loss, and treatable with a variety of effective drugs, rates of the disease remain stubbornly high.

Effective weight-loss programmes have proven hard to implement at large scale and many healthcare systems are not prepared to intervene in diabetes early, the researchers said. And while drugs such as those in the GLP-1 class made by Novo Nordisk A/S and Eli Lilly & Co have shown promising weight-loss results, costs put them out of reach for many patients, the authors said, and they haven’t been used widely enough to determine whether they can turn the tide. 

Addressing racism and economic inequality will be important for controlling diabetes, researchers from the US, Africa, India and Australia, wrote in a separate article in the same journal. People in low- and middle-income countries are more likely to suffer from the disease and its impacts, as are minority groups. 

There isn’t one perfect solution, Ong said. 

“Diabetes will always exist, and I think it is about managing and monitoring and identifying it early on,” she said.

More stories like this are available on bloomberg.com



Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Comment icon